AKTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Aktis Oncology Inc (AKTS) is a good buy for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. The company has strong positive catalysts including FDA Fast Track designation, strategic collaboration with Eli Lilly, and promising analyst ratings with high price targets. While technical indicators are bearish, the long-term growth potential in the radiopharmaceutical space outweighs short-term price movements.
The technical indicators for AKTS are bearish. The MACD histogram is -0.01 and below 0, showing weak momentum. RSI is at 10.21, indicating the stock is oversold. Moving averages are bearish with SMA_200 > SMA_20 > SMA_5. Support levels are at S1: 0.04 and S2: 0.02, while resistance levels are at R1: 0.09 and R2: 0.1.
FDA Fast Track designation for AKY-1189 to expedite development for urothelial cancer.
Strategic collaboration with Eli Lilly to develop novel radioconjugates.
Analysts have initiated coverage with strong buy ratings and price targets ranging from $30 to $
The company is entering a promising radiopharmaceutical space with first-in-class potential.
Weak financial performance in Q1 2025, including a net income drop of -68.11% YoY and EPS decline of -85.71%.
Bearish technical indicators suggest short-term price weakness.
No significant hedge fund or insider trading activity to indicate strong institutional interest.
In Q1 2025, revenue increased by 28.92% YoY to $9,027,000, indicating growth potential. However, net income dropped by -68.11% YoY to -$6,420,000, and EPS declined by -85.71% YoY to -0.04. Gross margin also dropped significantly to 47.66%, down -407.88% YoY, reflecting profitability challenges.
Analysts are highly optimistic about AKTS. JPMorgan, TD Cowen, Leerink, and BofA all initiated coverage with Buy or Overweight ratings. Price targets range from $30 to $34, indicating significant upside potential. Analysts highlight the company's innovative platform, first-in-class potential, and blockbuster opportunities in radiopharmaceutical therapies.
